NCT04311411

A Study of Tirzepatide in Overweight and Very Overweight Participants

Effect of Tirzepatide on Energy Intake and Appetite-and Reward-Related Brain Areas in Overweight/Obese Subjects: A Placebo-Controlled 6-Week Study With Functional MRI

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 114 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to measure the effect of tirzepatide on food intake in participants who are overweight or very overweight. The study will also use imaging to learn more about how tirzepatide affects specific parts of the brain. The effect of tirzepatide on appetite will also be studied. The study will last up to about four months and will include up to 14 visits to the study center.

Conditions

• Obesity
• Overweight

Interventions

Type	Name	Description
DRUG	Tirzepatide	Administered SC.
DRUG	Placebo	Administered SC.
DRUG	Liraglutide	Administered SC.

Timeline

• Start date: 2020-08-24
• Primary completion: 2022-12-16
• Completion: 2022-12-16
• First posted: 2020-03-17
• Last updated: 2024-05-22
• Results posted: 2024-05-22

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study